Introduction
The CB 2 receptor is a seven-transmembrane-domain G-proteincoupled receptor. 1 It is part of the endocannabinoid system which consists of another cannabinoid receptor (CB 1 ), endogenous agonist ligands derived from arachidonic acid (endocannabinoids) and a mechanism of deactivation involving enzymes and membrane transport system. 2 The gene encoding the human cannabinoid CB 2 receptor was cloned in 1993. 3 The CB 1 receptor is largely present in the central nervous system (CNS) with high density in the brain causing the well known psychotropic side-effects associated with the use of cannabis derivatives which are agonists to the receptor. 4 It has been thought for some time that the CB 2 receptor is absent from the CNS and it is abundant in the immune system. 5 More recent studies have suggested that CB 2 is also expressed in certain subpopulations of the CNS. 6 Together with this discovery and the understanding of the mechanism involved, the potential of therapeutic uses for CB 2 has increased. It has been shown that the expression of CB 2 receptors increases with the degree of malignancy in glial 7 and breast 8 tumors and that activation of the receptor could stop the tumor progression 7, 9 or induce apoptosis of the cancerous cells. 5 Cannabinoid receptor activation has also been suggested in therapeutic approaches in the treatment of pain, 10 inflammation, 11 osteoporosis 12 or sclerosis. 13 These observations have spurred wide spread interest in synthetic CB 2 -selective cannabinoid receptor specific molecules that act as agonists, inverse agonists, antagonists or simply new drugs for clinical use. [14] [15] [16] [17] Recently, Salo et al. 18 have used a comparative model of CB 2 receptor constructed using the bovine rhodopsin X-ray structure to identify new hit compounds. After virtual screening of chemical databases for hit molecules, the results of [ 35 ]GTPcS G-protein activations assays showed that one of them acted as a selective CB 2 agonist (NRB-04079, 2). This rather small isoquinolinyl phenyl ketone was suitable for pharmacomodulation together with its quinoline analogue NRB-04080 (1) which also showed CB 2 agonist properties and no sign of CB 1 activity ( Fig. 1 ). We report here the synthesis and the biological evaluation of such derivatives.
Results

Chemistry
In this study we investigated the modifications on the benzene ring of the phenyl quinolinyl ketones, which can be synthesized by
a Grignard coupling of an appropriate arylmagnesium halide and quinoline-2-carbonitrile 3 (Scheme 1).
The carbonitrile 3 was obtained from quinoline through N-oxidation followed by in situ conversion to an N-benzoate and addition of cyanide (Scheme 2). The oxidation of quinoline was more efficient with m-CPBA (after 30 min no more starting material was detected by TLC, 74% yield) than with hydrogen peroxide (3 days, 60% yield). The N-oxide was used without purification and 3 was obtained in high yield. Similarly, the isoquinolinyl carbonitrile 4 was obtained by oxidation of isoquinoline with m-CPBA and treatment with potassium cyanide and benzoyl chloride (Scheme 3).
The coupling reaction to give the isoquinolinyl aryl ketones involved the formation of a Grignard reagent from adequately substituted bromobenzenes (Scheme 4). Addition to the carbonitrile (3 or 4) led to the corresponding imine which gave the desired ketone upon hydrolysis with 1 M HCl. The reaction was conducted in a mixture of THF/toluene 1:2 in order to enhance the reactivity of the nucleophile toward the nitrile. 19 
Pharmacology
The new quinolinyl and isoquinolinyl phenyl ketones have been tested for their capacity of G-protein activation of the human CB 2 receptor (hCB 2 ) via a [ 35 ]GTPcS binding assay according to the procedure described by Savinainen et al. 20 The receptors used were hCB 2 stably expressed in Chinese hamster ovary (CHO) cells. In this assay, the effects of the tested cannabinoid agonists are obtained from agonist-induced binding of the nonhydrolyzable GTP ana-logue [ 35 ]GTPcS. The relative efficacy responses of the molecules are expressed as percentage of the full (both CB 1 and CB 2 ) potent cannabinoid agonist HU-210. All the compounds were first evaluated at 10 lM concentration. For the compounds that showed over 50% relative activity, the dose response curves were generated and the EC 50 and E max values were calculated by nonlinear regression analysis with the equation for a sigmoidal concentration-response curve (GRAPHPAD PRISM 4). The possible CB 1 receptor agonist and antagonism of all the compounds were screened at 10 lM concentration in rat cerebellar membranes as previously described 21 to estimate the CB 2 selectivity of the compounds.
Discussion
We have synthesized two series of compounds that are listed together with their yields and their efficacy results in Table 1 (quinolines) and Table 2 (isoquinolines).
Quinolines
Both electron donating and electron withdrawing substituents were evaluated. Of the 4-substituted molecules, the best compound (5k, Àlog EC 50 = 5.4, E max = 62) possesses an electron donating NMe 2 group. An electron-withdrawing 4-chloro substituent (5m) and electron-donating 4-methoxy substituent (5e) also maintain considerable relative activity, whereas electron-withdrawing 4-CF 3 (5b) and 4-F substituents (5o) showed weaker activity.
Moving the CF 3 group from the 4-position to the 3-position (2) led to slight improvement in CB 2 activity whereas introducing CF 3 to the 2-position (5c) gives a potent high efficacy ligand (Àlog EC 50 = 5.7, E max = 87). That pattern is also apparent with electron-donating substituents. Moving a methoxy group from the 4-position (5e) to the 3-position (5f) and then to the 2-position (5g) leads to improved activity. The gain in CB 2 efficacy and potency is even better when 4-NMe 2 substituent is moved to 2-position (5l, Àlog EC 50 = 6.1, E max = 91). Moving 4-chloro (5m) to 2position (data not shown) or 4-fluoride (5j) to 3-position (5i) does not noticeably improve the CB 2 activity.
Elongation of the alkoxy group at the 4-position (5h, 5i and 5j) leads to loss of CB 2 activity. Those observations suggest that the binding area of the CB 2 receptor is not sensitive to the electronic nature of the compounds but more likely to the size and shape and is intolerant to steric bulk. This assertion is supported by the bis-functionalized molecules 5d (3,5-CF 3 ) and 5n (3,4-Cl) which lose almost all activity.
Isoquinolines
The 4-CF 3 analogue 6b (Àlog EC 50 = 5.5, E max = 57) seems to be equipotent with the 3-CF 3 hit 2 (Àlog EC 50 = 5.3, E max = 53) but like in the quinoline series, the 2-CF 3 analogue 6c has higher CB 2 potency and efficacy (Àlog EC 50 = 6.3, E max = 72). A further 3-CF 3 is still responsible for a dramatically drop of the activity (6d). Overall, the isoquinoline compounds show approximately the same efficacy and potency as the quinoline analogues with the exception or of the 4-methoxy analogue 6e which has very weak potency. The same observations can be made regarding the non-influence of the electronic nature of the substituents (6b and 6g have the same relative agonist activity) and the large impact of its position on the benzene ring as can be seen by comparing the compounds 6h and 6g. We finally observe that the 2-NMe 2 analogue 6h has higher potency and efficacy (Àlog EC 50 = 6.2, E max = 95) than the 4-NMe 2 analogue 6g (Àlog EC 50 = 5.6, E max = 68) as was the case in quinoline series.
Conclusions
The pharmacomodulation of the hit compounds 1 and 2 was achieved to give better agonist capacity (E max >42, Àlog EC 50 >5.3 for the quinoline series; E max >53, Àlog EC 50 >5.3 for the isoquinoline series). However, only compounds 5l, 6h and 5c are full CB 2 agonists (respectively E max = 91, 95 and 87). None of these compounds showed any significant CB 1 receptor activation.
In conclusion, the quinolinyl and isoquinolinyl phenyl ketones represent a new class of CB 2 -selective receptor ligands, which revealed full or partial CB 2 cannabinoid receptor agonistic properties in the [ 35 ]-GTPcS binding assay. Both isoquinoline and quinoline derivatives showed more or less same efficacy and potency. The most potent ligands were the 2-NMe 2 substituted compounds (5l and 6h).
Experimental
General methods
All reactions were carried out under an atmosphere of argon in flame-dried glassware. Non-aqueous reagents were transferred under argon via syringe or cannula and dried prior to use. THF was distilled from Na/benzophenone ketyl. CH 2 Cl 2 and MeOH were dis-tilled from CaH 2 . All other solvents and reagents were used as obtained from the supplier. Analytical TLC was performed on Merck silica gel F254 (230-400 mesh) plates and visualized under UV light. Flash chromatography was performed on Merck Silica Gel 60 (230-400 mesh) and p.a. grade solvents. Infrared spectra were measured on a Perkin Elmer Spectrum One FT-IR spectrometer using KBr disc. The 1 H and 13 C NMR spectra were recorded in a CDCl 3 solution on a Bruker Avance 400 ( 1 H 399.98 MHz; 13 C 100.59 MHz) spectrometer. Chemical shifts are reported in ppm relative to tetramethylsilane (d 0) for 1 H NMR. For the 13 C NMR spectra, the signal for CDCl 3 (d 77.16) was used as the internal standard. High-resolution mass spectrometric data were obtained on Waters LCT Premier-spectrometer. Melting points were obtained on Gallenkamp and Stuart SMP3 melting point apparatuses. The elemental analyses were performed at the Analytical Services of the Department of Chemical Technology, Laboratory of Organic Chemistry.
Quinoline-2-carbonitrile (3)
To a solution of quinoline (1.50 g, 11.6 mmol, 100 mol %) in 15 mL of CH 2 Cl 2 was added m-CPBA (70% with water, 2.87 g, 11.6 mmol, 100 mol %) portionwise. After 2 h, the solution was dried with Na 2 SO 4 , filtered and evaporated. The solid obtained was dissolved in acetonitrile (51 mL) and added to a solution of KCN (1.51 g, 23.2 mmol, 200 mol %) in methanol (39 mL). Benzoyl chloride (2.70 mL, 23.2 mmol, 200 mol %) was added dropwise and the reaction was stirred overnight. After evaporation of the solvent, the residue was taken up in CH 2 Cl 2 and washed twice with a solution of saturated NaHCO 3 . The organic layer was dried over Na 2 SO 4 , filtered, and evaporated in vacuo. The residue was purified by column chromatography (hexane/EtOAc, 9:1) affording compound 3 (1.47 g, 82%) as a white solid. 1 3-F 98 106 ± ± 2 34 ± 5 n.d. n.d.
Isoquinoline-1-carbonitrile (4)
This was prepared from isoquinoline (1.50 g, 11.6 mmol) following the same procedure as for quinoline-2-carbonitrile 3 to give isoquinoline-1-carbonitrile 4 (1.23 g, 68%) as a white solid. 1 
General procedure for the quinolinyl and isoquinolinyl phenyl ketones
A solution of the appropriate bromophenyl derivative (1.43 mmol, 200 mol %) in 1.5 mL of THF was treated with magnesium (1.71 mmol, 240 mol %). After the formation of the Grignard reagent, the solution was added to a solution of the appropriate carbonitrile (0.713 mmol, 100 mol %) in toluene (3 mL) at 0°C. When TLC showed no more starting material, the reaction was quenched by addition of a solution of satd NH 4 Cl. The organic layer was separated and extracted twice with CH 2 Cl 2 . After evaporation, the organic layer was redissolved in Et 2 O (10 mL) and 1 M HCl (4 mL) was added. After 20 min, the organic layer was separated; the aqueous layer basified with saturated NaHCO 3 and then extracted three times with CH 2 Cl 2 . The combined organic layers were dried over Na 2 SO 4 and evaporated in vacuo. The residue was purified by column chromatography (hexane/EtOAc) and crystallized.
Quinolin-2-yl-(4-trifluoromethylphenyl)-methanone (5b)
This was prepared from quinoline-2-carbonitrile and 4-bromobenzotrifluoride in 80% yield. White needles; mp 99°C (hexane); IR 
